Retigabine is used as an anticonvulsant medication in the treatment of epilepsy, specifically as an adjunctive therapy for partial-onset seizures in adults. It works by enhancing the activity of potassium channels in the brain, particularly the KCNQ (Kv7) channels, which helps stabilize neuronal membranes and reduce excessive electrical activity that leads to seizures. Due to its unique mechanism of action, it is prescribed when other anti-epileptic drugs are not fully effective. However, its use has been limited in some regions due to safety concerns, including potential retinal abnormalities and skin discoloration with long-term use.